Rhythm Pharmaceuticals
Update in progressRYTM (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases in the United States and abroad. Its lead candidate, IMCIVREE (setmelanotide), targets MC4R pathway deficiencies causing obesity and is in Phase 3 for several hypothalamic obesity and MC4R-deficiency conditions, and Phase 2 for Prader-Willi syndrome. It also develops bivamelagon (oral MC4R agonist) in Phase 2 and RM-718 (MC4R peptide agonist) in Phase 1 for hypothalamic obesity. Formerly Rhythm Metabolic, renamed Rhythm Pharmaceuticals in 2015. Founded 2008, Boston.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.37
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!